Smyrna, TN

Advancing Vision Research, LLC

Dry Eye Syndromes

Eye Diseases

Keratoconjunctivitis Sicca

TL-925

AR-15512

Aerie Pharmaceuticals

Telios Pharma

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID.

The study will comprise two phases: a two-week screening phase/run-in and a six-week double-masked treatment phase.

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Advancing Vision Research, LLC | Smyrna, TN

Site insights

Work at this site?

Active trials

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Trial sponsors